ORAGENICS INC
For the period ended Mar 31, 2026. Filed May 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 8, 2026
OGEN$0.35+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| (Unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $6,107,078 | $4,399,726 |
| Short-term investment | - | 4,000,000 |
| Interest receivable | - | 53,082 |
| Prepaid expenses and other current assets | 1,382,558 | 1,614,956 |
| Total current assets | 7,489,636 | 10,067,764 |
| Total assets | $7,489,636 | $10,067,764 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $1,251,744 | $1,559,011 |
| Short-term notes payable, net of debt issuance costs | 56,134 | 227,348 |
| Total liabilities | 1,307,878 | 1,786,359 |
| Stockholders’ equity: | ||
| Preferred stock, no par value; 50,000,000 shares authorized; 428,291 Series H and 7,488,692 Series F outstanding at March 31, 2026, and 429,291 Series H and 7,488,692 Series F outstanding at December 31, 2025. | - | - |
| Common stock, $0.001 par value; 350,000,000 shares authorized; 4,375,729 and 4,271,529 shares issued and outstanding at March 31, 2026, and December 31, 2025, respectively | 4,375 | 4,271 |
| Additional paid-in capital | 235,007,285 | 234,905,793 |
| Accumulated deficit | (228,829,902) | (226,628,659) |
| Total stockholders’ equity | 6,181,758 | 8,281,405 |
| Total liabilities and stockholders’ equity | $7,489,636 | $10,067,764 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.